Eli Lily gets key prescription weigh-loss approval
The US Food and Drug Administration approved Eli Liliy's weight loss drug on Wednesday.
The drug approved, tirzepatide, had already been approved for Type 2 diabetes under the trade name Mounjaro. The drug recently contributed to Eli Lily's boosted sales outlook as demand for prescription weight loss drugs has been a hot topic on Wall Street. Goldman Sachs estimated 15 million Americans will be taking weight loss drugs by 2030.
Eli Lily (LLY) shares popped more than 1% on the news while competitor Novo Nordisk (NVO) saw shares slide more than 1%.
Eli Lily gets key prescription weigh-loss approvalThe US Food...
-
- There are more pages in this discussion • 8,873 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
4.9¢ |
Change
0.001(2.08%) |
Mkt cap ! $364.4M | |||
| Open | High | Low | Value | Volume |
| 4.8¢ | 4.9¢ | 4.8¢ | $179.8K | 3.692M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 62 | 8124186 | 4.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 4.9¢ | 3070575 | 9 |
View Market Depth
| Last trade - 16.10pm 11/10/2024 (20 minute delay) ? |
| IMU (ASX) Chart |